Haoma Medica completes first-in-human trial of NaQuinate, a promising osteoporosis treatment

Haoma Medica, a UK-based biotechnology company, has successfully wrapped up the first-in-human clinical trial of NaQuinate, a novel oral treatment designed to address osteoporosis. This drug, derived from naphthoquinone carboxylic acid, has shown promise as a potential therapeutic solution for the bone disease that often goes undiagnosed until fractures occur. With the completion of this crucial trial phase, the company is now one step closer to advancing NaQuinate as an innovative option for those suffering from osteoporosis.

The First-in-Human Trial: Safety and Tolerability Results

The trial, which began in late 2023, involved administering NaQuinate to healthy adults in both single and multiple doses. The primary focus of the study was to assess the safety, tolerability, and pharmacokinetics of the drug, which would establish the foundation for future clinical investigations. According to Dr. Cenk Oguz, Haoma Medica’s Chief Medical Officer, the company is “delighted” with the outcome of the trial, as there were “no significant safety or tolerability concerns up to the highest doses tested.” This outcome underscores the company’s expectation that NaQuinate is not only safe but well tolerated by the human body.

The fact that the trial achieved these positive results in healthy volunteers is a significant step forward in the development of NaQuinate as a potential treatment for osteoporosis. The absence of adverse reactions at the highest doses tested offers crucial reassurance about the drug’s suitability for further clinical exploration in patients with osteoporosis.

Understanding Osteoporosis and the Potential of NaQuinate

Osteoporosis is often referred to as a “silent disease” because it typically doesn’t exhibit symptoms until a bone fracture occurs, leading to its underdiagnosis and undertreatment. The condition, which causes bones to become weak and brittle, is particularly prevalent in postmenopausal women due to hormonal changes that affect bone density. With the growing global elderly population, osteoporosis is becoming an increasingly important public health concern, highlighting the need for effective treatments.

NaQuinate, as a potential solution, works by targeting bone loss mechanisms and promoting bone formation. This oral drug candidate has already demonstrated efficacy in pre-clinical studies, particularly in rodent models where it protected against bone deterioration following ovariectomy. This animal model simulates the hormonal changes seen in postmenopausal women, making it highly relevant for osteoporosis treatment.

The Mechanism of Action: A ‘Smart’ Drug for Bone Health

Dr. Steve Deacon, Haoma Medica’s CEO, elaborated on NaQuinate’s unique mechanism of action, calling it a “smart” drug for osteoporosis treatment. Pre-clinical research has revealed that NaQuinate works synergistically with the body’s natural response to mechanical loading, such as weight-bearing exercise. This interaction results in enhanced bone formation when and where the body needs it most, particularly in the relevant cortical bone regions.

The synergy between NaQuinate and the body’s mechanostat—a biological system that helps bones adapt to mechanical stress—could offer significant benefits in maintaining bone health and preventing fractures. Dr. Deacon stated, “Together with the safety data from this first-in-human study, this supports the potential that NaQuinate treatment could provide a safe, novel and smart therapeutic approach to bone disorders like osteoporosis and better maintain healthy skeletal aging.”

This innovative approach could set NaQuinate apart from traditional osteoporosis treatments, offering a more dynamic and tailored method for preserving bone integrity over time.

Looking Ahead: The Future of NaQuinate

With the completion of the first-in-human trial, Haoma Medica is now preparing for the next phases of clinical testing, which will focus on evaluating the drug’s effectiveness in individuals diagnosed with osteoporosis. The promising safety profile and unique mechanism of action demonstrated so far place NaQuinate in a strong position to compete in the osteoporosis treatment space.

The global osteoporosis market is expected to grow significantly as the aging population increases, making the development of novel treatments like NaQuinate an essential step in addressing this public health challenge. If future trials continue to yield positive results, NaQuinate could become a game-changer in the way osteoporosis is managed, offering a safer, more effective treatment option for millions of people worldwide.

Haoma Medica’s breakthrough with NaQuinate could ultimately revolutionize osteoporosis care, providing a novel, smart approach to maintaining bone health and reducing the risks associated with the disease. As the company moves forward with its clinical program, the medical community and osteoporosis patients alike will be closely watching the results, hopeful for a new and better way to manage this often-overlooked condition.